VAERS data released Friday by the Centers for Disease Control and Prevention included a total of 1,205,755 reports of adverse events from all age groups following COVID vaccines, including 26,396 deaths and 214,521 serious injuries between Dec. 14, 2020, and March 25, 2022.
The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,205,755 reports of adverse events following COVID vaccines were submitted between Dec. 14, 2020, and March 25, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.
The data included a total of 26,396 reports of deaths — an increase of 337 over the previous week — and 214,521 of serious injuries, including deaths, during the same time period — up 2,937 compared with the previous week.
Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.
Of the 12,103 U.S. deaths reported as of March 25, 17% occurred within 24 hours of vaccination, 21% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.
In the U.S., 559 million COVID vaccine doses had been administered as of March 18, including 330 million doses of Pfizer, 210 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).
U.S. VAERS data from Dec. 14, 2020, to March 25, 2022, for 5- to 11-year-olds show:
- 9,771 adverse events, including 234 rated as serious and 5 reported deaths. The most recent death involves a 7-year-old boy (VAERS I.D. 2152560) from Washington who died 13 days after receiving his first dose of Pfizer’s COVID vaccine when he went into shock and suffered cardiac arrest. He was unable to be resuscitated and died in the emergency department.
- 17 reports of myocarditis and pericarditis (heart inflammation). The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.
- 37 reports of blood clotting disorders.
U.S. VAERS data from Dec. 14, 2020, to March 25, 2022, for 12- to 17-year-olds show:
- 30,771 adverse events, including 1,771 rated as serious and 43 reported deaths.
The most recent death involves a 17-year-old boy (VAERS I.D. 2189006) from Georgia who “suddenly died in his sleep” six months after receiving his second dose of Pfizer’s COVID vaccine. The boy had an autopsy but the results were not disclosed. He had no underlying health conditions.
- 68 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine.
- 650 reports of myocarditis and pericarditis, with 638 cases attributed to Pfizer’s vaccine.
- 165 reports of blood clotting disorders, with all cases attributed to Pfizer.
U.S. VAERS data from Dec. 14, 2020, to March 25, 2022, for all age groups combined, show:
- 20% of deaths were related to cardiac disorders.
- 54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
- The average age of death was 72.7.
- As of March 25, 5,341 pregnant women reported adverse events related to COVID vaccines, including 1,687 reports of miscarriage or premature birth.
- Of the 3,637 cases of Bell’s Palsy reported, 51% were attributed to Pfizer vaccinations, 40% to Moderna and 8% to J&J.
- 874 reports of Guillain-Barré syndrome, with 42% of cases attributed to Pfizer, 30% to Moderna and 28% to J&J.
- 2,373 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 1,655 reports of myocardial infarction.
- 13,657 reports of blood-clotting disorders in the U.S. Of those, 6,104 reports were attributed to Pfizer, 4,871 reports to Moderna and 2,638 reports to J&J.
- 4,088 cases of myocarditis and pericarditis with 2,511 cases attributed to Pfizer, 1,388 cases to Moderna and 179 cases to J&J’s COVID vaccine.
Woman dies from rare brain disorder after second Pfizer shot
In an exclusive interview with The Defender, Richard Sprague said his wife, Jennifer, developed Creutzfeldt-Jakob Disease (CJD) after her second Pfizer shot and died within five months of the second dose.
Jennifer, a healthy 60-year-old woman from Missouri, experienced her first “event she couldn’t explain” four days after receiving the second Pfizer dose. Over the following weeks, her symptoms worsened until she could no longer work, pour coffee or walk without assistance.
Jennifer was later hospitalized and diagnosed with CJD, a fatal prion disease that causes degeneration of the brain. Her health rapidly deteriorated until she could no longer sit up on her own or communicate.
When Jennifer’s insurance would no longer cover her injury, she was placed on hospice and sent home. She died Feb. 21.
Sprague, who remains unvaccinated, encouraged others to avoid COVID vaccines unless they have full knowledge of potential adverse events and an understanding that the vaccine is experimental.
Heart damage found in teens months after second Pfizer shot
A new peer-reviewed study published March 25 in the Journal of Pediatrics showed more than two-thirds of adolescents with COVID vaccine-related myopericarditis had persistent heart abnormalities months after their initial diagnosis — raising concerns for potential long-term effects.
Researchers at Seattle Children’s Hospital reviewed cases that occurred between April 1, 2021, and Jan. 7, 2022, of patients younger than 18 who presented to the hospital with chest pain and an elevated serum troponin level within one week of receiving a second dose of Pfizer’s vaccine.
While 35 patients fit the criteria, 19 were excluded for various reasons. Cardiac magnetic resonance imaging (MRI) of the remaining 16 patients was performed three to eight months after they were first examined.
The MRIs showed 11 had persistent abnormal findings and late gadolinium enhancement (LGE), although levels were lower than in previous months.
According to the study, “The presence of LGE is an indicator of cardiac injury and fibrosis and has been strongly associated with worse prognosis in patients with classical acute myocarditis.”
Pfizer’s COVID vaccine less effective against Omicron for children 12 and older
The study, funded by the CDC, involved 1,185 patients, 88% of whom were unvaccinated.
During the “Delta-predominant period” (July 1 to Dec. 18, 2021), researchers reported vaccine effectiveness against hospitalization for COVID among adolescents 12 to 18 years old was 93% two to 22 weeks after vaccination.
During the “Omicron-predominant period” (Dec. 19, 2021, to Feb. 17), among adolescents in the same age group, vaccine effectiveness fell to 40% against hospitalization for COVID, 79% against critical COVID and 20% against noncritical COVID. This group’s median interval since vaccination was 162 days.
Incurable neurological disorder, aphasia, linked to COVID vaccines
News Wednesday that actor Bruce Willis was diagnosed with aphasia, requiring him to “step away” from his career, cast a spotlight on the incurable neurological disorder, which has also been linked to COVID-19 and COVID vaccines.
According to the National Institute of Deafness and Other Communication Disorders, aphasia is a disorder that results from damage to areas of the brain responsible for language.
The condition often occurs suddenly, but frequently follows a stroke or head injury, or could occur as a result of a brain tumor or progressive neurological disease.
Moderna weighing vax for kids under 6
Moderna last week said it will seek Emergency Use Authorization (EUA) for its COVID-19 pediatric vaccine, after announcing its two-dose regimen reduced cases of symptomatic disease by 43.7% in children 6 months to 2 years old and by 35.7% in children ages 2 to 6.
The company said its Phase 2/3 KidCOVE study of its mRNA-1273 in children “successfully met its primary endpoint.”
However, as Politico reported Wednesday, and as experts told The Defender, some doctors and scientists question whether Moderna’s clinical trial data will be sufficient for the U.S. Food and Drug Administration (FDA) to grant EUA for the vaccine.
Experts cited the trials’, small sample size, low efficacy rates and reliance on a research workaround called immunobridging as weaknesses that could hinder Moderna’s case.
“Given the other data that surrounds it, I don’t know that it’s a slam dunk that the FDA will move forward in terms of releasing it for emergency use,” Peter Hotez, professor of pediatrics and molecular virology and microbiology at the Baylor College of Medicine, told Politico.
“We’re still learning about the relationship between virus-neutralizing antibodies and effectiveness,” Hotez said, adding the FDA might need to raise its standards.
Multiple experts also raised questions about the risk-benefit ratio of the COVID vaccines for an age group with a statistically insignificant risk of severe illness.
© 2022 Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.